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Summary
Background: The mammalian target of rapamycin (mTOR) is
a Ser/Thr kinase that controls cell growth in response to mito-
gens, as well as amino acid and energy sufficiency. The scaf-
folding protein Raptor binds to mTOR and recruits substrates
to the rapamycin-sensitive mTOR complex 1 (mTORC1). Al-
though Raptor has been shown to be essential for mTORC1
activity, the mechanisms regulating Raptor function remain
unknown.
Results: Here, we demonstrate that Raptor becomes highly
phosphorylated on RXRXXpS/T consensus motifs after activa-
tion of the Ras/mitogen-activated protein kinase (MAPK) path-
way. Using pharmacological inhibitors and RNA interference,
we show that the p90 ribosomal S6 kinases (RSKs) 1 and 2
are required for Raptor phosphorylation in vivo and directly
phosphorylate Raptor in vitro. Quantitative mass spectrometry
and site-directed mutagenesis revealed that RSK specifically
phosphorylates Raptor within an evolutionarily conserved re-
gion with no previously known function. Interestingly, expres-
sion of oncogenic forms of Ras and MEK that elevate mTORC1
activity induced strong and constitutive phosphorylation of
Raptor on these residues. Importantly, we demonstrate that
expression of Raptor mutants lacking RSK-dependent phos-
phorylation sites markedly reduced mTOR phosphotransfer-
ase activity, indicating that RSK-mediated phosphorylation
of Raptor is important for mTORC1 activation by the Ras/
MAPK pathway.
Conclusions: We propose a unique mode of mTOR regulation
in which RSK-mediated phosphorylation of Raptor regulates
mTORC1 activity and thus suggest a means by which the
Ras/MAPK pathway might promote rapamycin-sensitive
signaling independently of the PI3K/Akt pathway.
Introduction
The mammalian target of rapamycin (mTOR) is a conserved
Ser/Thr kinase that integrates signals from nutrients, energy
sufficiency, and growth factors to regulate mammalian cell
growth as well as organ and body size in a variety of organisms
[1, 2]. mTOR was discovered as the molecular target of
*Correspondence: philippe.roux@umontreal.carapamycin, an antifungal agent used clinically as an immuno-
suppressant and, more recently, as an anti-cancer drug [3].
Emerging evidence indicates that deregulation of the mTOR
pathway occurs in many types of cancer [4, 5], underscoring
the importance of understanding how this pathway is regu-
lated by oncogenic and mitogenic cues.
mTOR forms two distinct multiprotein complexes, the rapa-
mycin-sensitive and -insensitive mTOR complexes (mTORCs)
1 and 2, respectively [6]. mTORC1 consists of the mTOR cata-
lytic subunit and three associated proteins, Raptor, mLST8,
and PRAS40. Activated mTORC1 phosphorylates two main
regulators of mRNA translation and ribosome biogenesis,
S6K1 and 4E-BP1, and thus stimulates protein synthesis [7,
8]. The molecular functions of most mTOR-associated pro-
teins are not understood, but Raptor has been proposed to
work as a scaffolding protein that recruits mTOR substrates
through their TOR signaling (TOS) motif [9, 10]. Inhibition of
Raptor expression with RNA interference (RNAi) decreases
mTORC1 activity and reduces cell size, indicating that Raptor
is an essential mediator of mTORC1 action in vivo and plays
a crucial role in mTOR activation [11–13]. However, the molec-
ular mechanisms by which Raptor regulates mTORC1 activity
and how Raptor function is modulated by growth factors and
oncogenes remain unknown.
The mechanisms underlying mTORC1 regulation are not
fully understood, but the key upstream player appears to be
the small GTPase Rheb, which is negatively regulated by the
dimeric TSC1-TSC2 GTPase-activating protein (GAP) complex
[14]. It is now appreciated that several pathways in addition to
the insulin-stimulated PI3K/Akt pathway signal to mTORC1 by
modulating TSC1-TSC2 activity toward Rheb. For example,
energy deprivation sensed by AMPK [15] and hypoxia [16]
regulate TSC1-TSC2 activity and Rheb GTP loading. More-
over, the Ras/MAPK signaling pathway positively regulates
mTORC1 activity through extracellular signal-regulated kinase
(ERK)- and p90 ribosomal S6 kinase (RSK)-mediated phos-
phorylation and inactivation of TSC2 [17–21].
Herein, we describe a novel link between the Ras/MAPK
pathway and mTORC1 signaling. We demonstrate that Raptor
is phosphorylated mainly on three serine residues by the RSK1
and RSK2 protein kinases in vitro and in vivo. We find that
RSK-mediated phosphorylation of Raptor positively regulates
mTORC1 kinase activity stimulated by the Ras/MAPK path-
way. Our findings suggest a unique mode of mTOR regulation
by which Raptor acts as a molecular sensor that integrates
growth signals and promotes mTORC1 signaling.
Results
An Approach Involving a Phospho-Motif Antibody
Identifies Raptor as a Substrate of Ras/MAPK Signaling
We analyzed Raptor phosphorylation by using an antibody that
recognizes the phosphorylated consensus motif Arg/Lys-X-
Arg/Lys-X-X-pSer/Thr (RXRXXpS/T, where X is any amino
acid), which is found in substrates of many AGC family kinases,
including RSK [20], Akt, and S6K1 [22]. HEK293 cells trans-
fected with Myc-tagged Raptor were stimulated with different
mitogens and growth factors, and immunoprecipitated Raptor
Figure 1. RSK Phosphorylates Raptor In Vitro and in Cells Stimulated with Agonists of the Ras/MAPK Pathway
(A) HEK293 cells were transfected with empty vector or Myc-tagged Raptor, serum-starved, and stimulated for 10 or 20 min with agonists of the Ras/MAPK
and PI3K/Akt signaling pathways. Immunoprecipitated Raptor was then assayed for phosphorylation with a phospho-motif antibody that recognizes the
RXRXXpS/T consensus motif.
(B and C) As in (A), but cells were pretreated with U0126 (10 mM), rapamycin (100 nM), or BI-D1870 (10 mM) for 30 min prior to PMA (50 ng/ml) stimulation.
(D) HEK293 cells were cotransfected with control vector or Myc-tagged Raptor, and siRNA duplexes were targeted against a scrambled sequence (Scr),
RSK1 or RSK2, serum-starved, and stimulated with PMA (50 ng/ml). Immunoprecipitated Raptor was then assayed as in (A).
(E) HEK293 cells were cotransfected with Raptor and wild-type RSK1, constitutively activated RSK1 (myr), or kinase-inactive RSK1 (kd), serum starved, and
stimulated with PMA (50 ng/ml). Immunoprecipitated Raptor was then assayed as in (A).
(F) Immunoprecipitated HA-tagged wild-type or kinase-dead RSK1 (kd) from PMA-stimulated cells was incubated with immunopurified Raptor in a kinase
reaction with g[32P]ATP. The resulting samples were subjected to SDS-PAGE, and the dried Coomassie-stained gel was autoradiographed.
(G) Samples were treated as in (F), but kinase reactions were performed without radioactivity. The resulting samples were immunoblotted for Raptor
phosphorylation on RXRXXpS/T consensus sites.
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1270was analyzed for phosphorylation via immunoblotting with the
RXRXXpS/T phospho-motif antibody. Using this method, we
found that potent Ras/MAPK-pathway agonists, such as the
phorbol ester PMA and epidermal growth factor (EGF), robustly
stimulated Raptor phosphorylation at RXRXXpS/T consensus
sites in HEK293 cells (Figure 1A), as well as in HeLa and NIH
3T3 cells (data not shown). This antibody specifically recog-
nized phosphorylated Raptor, as demonstrated by the fact
that phosphatase treatment of immunoprecipitated Raptor re-
sulted in a complete loss of immunoreactivity (Figure S1A in the
Supplemental Data). Because EGF also weakly stimulates the
PI3K/Akt pathway, we tested serum and insulin, which are po-
tent stimulators of Akt phosphorylation at Ser473, and found
that these agonists did not promote Raptor phosphorylation
(Figure 1A). To further assess the role of PI3K signaling in Rap-
tor phosphorylation, we treated cells with increasing concen-
trations of insulin or transfected them with a constitutivelyactivated form of Akt (myristoylated Akt). As shown in Fig-
ure S1B, whereasPMAstrongly stimulated theRas/MAPK path-
way and Raptor phosphorylation, no phosphorylation was
detected under conditions in which Akt phosphorylation was
potently stimulated. Together, these data strongly implicate
Raptor as a phosphorylation target of the Ras/MAPK pathway.
RSK1 and RSK2 Phosphorylate Raptor In Vivo and In Vitro
We next wanted to identify the kinase(s) responsible for Raptor
phosphorylation on RXRXXpS/T consensus motifs after activa-
tion of the Ras/MAPK pathway. Cells were pretreated with the
inhibitor U0126 to block MEK 1 and 2 downstream signaling. In-
terestingly, Raptor phosphorylation was almost completely
abrogated by U0126 treatment (Figure 1B), suggesting that a ki-
nase located downstream of MEK 1 and 2 is involved in Raptor
phosphorylation. RSK and S6K are two kinases stimulated by
MEK 1 and 2 signaling that are capable of phosphorylating
Raptor at RXRXXpS/T consensus motifs. To test their implica-
tion in Raptor phosphorylation, we pretreated cells with the
mTORC1 inhibitor rapamycin to inhibit mTOR-mediated S6K
activation. Although rapamycin treatment efficiently inhibited
S6K-mediated S6 phosphorylation at Ser240/44 (Figure 1B),
Raptor phosphorylation remained unaltered. Consistent with
a role for RSK, we found that treatment of cells with BI-
D1870, a recently identified pan-RSK inhibitor [23], completely
abolished Raptor phosphorylation upon PMA (Figure 1C) and
EGF treatments (data not shown). The RSK1–4 ATP antagonist
has recently been tested against a panel of more than 60 pro-
tein kinases and, remarkably, it was found to be very selective
for RSK family members when it was used on cells in the lowmM
range [24].
To confirm the direct involvement of RSK in Raptor phos-
phorylation, we used small interfering RNA (siRNA)-mediated
RNAi to specifically reduce expression of RSK1 and RSK2,
the two predominantly expressed isoforms of RSK in HEK293
cells [25]. Importantly, siRNA-mediated knockdown of RSK1
and RSK2 resulted in complete inhibition of Raptor phosphor-
ylation (Figure 1D), demonstrating that endogenous RSK1 and
RSK2 mediate Raptor phosphorylation in cells. To further
assess the role of RSK, we cotransfected HEK293 cells with
Raptor and different RSK mutants. Compared to the control,
expression of wild-type RSK1 (Figure 1E), as well as RSK2,
RSK3, and RSK4 (Figure S2A), specifically increased Raptor
phosphorylation after PMA stimulation, suggesting that Raptor
is a common RSK family substrate. Moreover, expression of
a constitutively activated form of RSK1 (myristoylated RSK1)
induced Raptor phosphorylation even in the absence of serum
and PMA stimulation (Figure 1E), consistent with the idea that
RSK is required and sufficient to stimulate Raptor phosphory-
lation in cells. RSK1 phosphotransferase activity was found to
Figure 2. Oncogenic Activation of the Ras/MAPK
Pathway Promotes Constitutive Raptor Phos-
phorylation
(A) Model depicting the Ras/MAPK pathway and
inhibitors and activators used in this study.
(B and C) HEK293 cells were cotransfected with
Raptor and constructs expressing activated
Ras (G12V), dominant-negative Ras (S17N), con-
stitutively activated MEK1 (MEK-DD), or control
vector and serum starved. Immunoprecipitated
Raptor from unstimulated cells was then assayed
for phosphorylation with the RXRXXpS/T phos-
pho-motif antibody.
(D) HEK293 cells were cotransfected with Raptor
and wild-type ERK2, serum starved, stimulated
with PMA, and analyzed as in (B).
(E) HEK293 cells were either cotransfected with
Raptor and MEK-DD, serum starved, and treated
with BI-D1870 for 60 min (left panel) or cotrans-
fected with control siRNA (Scr) or siRNAs tar-
geted against RSK1 and RSK2 and serum starved
(right panel). Immunoprecipitated Raptor was
then assayed for phosphorylation as in (B).
be required for stimulating Raptor phos-
phorylation: A RSK1 mutant with inacti-
vating mutations in both kinase domains
(K112/464R) [18] did not increase Raptor
phosphorylation over the level already
stimulated by endogenous RSK activity
(Figure 1E).
To verify that RSK could directly phosphorylate Raptor, we
performed in vitro kinase assays with purified proteins.
HEK293 cells were transiently transfected with wild-type or
kinase-inactive HA-tagged RSK1, and purified RSK1 from un-
stimulated or PMA-treated cells was incubated with full-length
Raptor immunopurified from serum-deprived cells. Although
no incorporation of [32P] label was seen in purified Raptor incu-
bated with unstimulated RSK1 or the kinase-inactive RSK1, we
found that activated RSK1 robustly increased [32P] incorpora-
tion in purified Raptor (Figure 1F). In a similar experiment
performed without radioactivity, we found that wild-type, but
not kinase-inactive, RSK1 robustly stimulated the phosphory-
lation of purified Raptor at RXRXXpS/T consensus sites (Fig-
ure 1G). These experiments were also performed with re-
combinant GST-Raptor as a substrate, and consistent with
aforementioned data, it was found to be an excellent in vitro
substrate for RSK (Figure S1C). Together, our data indicate
that RSK directly promotes Raptor phosphorylation in vivo
and in vitro at RXRXXpS/T consensus sites.
Constitutive Phosphorylation of Raptor in Cells with
Oncogenic Activation of the Ras/MAPK Signaling Cascade
Ras proteins are often mutated in human cancers such that
they constitutively activate growth signaling cascades, includ-
ing the MAPK, PI3K and mTOR pathways [26]. To determine
whether oncogenic forms of Ras and its downstream effector
kinase MEK stimulate Raptor phosphorylation, we transfected
cells with active (G12V) and inactive (S17N) mutants of H-Ras
or a constitutively activated form of MEK1 (MEK1-DD) (Fig-
ure 2A). Interestingly, we found that transient (Figures 2B
and 2C) or stable (data not shown) expression of either
RasG12V or MEK1-DD strongly stimulated Raptor phosphory-
lation in the absence of serum or growth factors. Additionally,
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Figure 3. Quantitative Mass Spectrometry Identifies and Profiles the Phosphorylation of Raptor upon Stimulation of the Ras/MAPK Pathway
(A) Schematic representation of ion mapping and intensity normalization for determining changes in phosphorylation upon PMA stimulation and kinase
inhibitor treatment.
(B) Abundance ratios of different modified and invariant Raptor tryptic peptides normalized to unstimulated cells. A dotted line indicates no changes in
abundance ratio. Results from three independent replicates are represented in a histogram as the means 6 standard error.
(C and D) MS/MS spectra of doubly protonated precursor at m/z 666.3 (C) and m/z 706.3 (D) corresponding to tryptic peptides LRpSVSSYGNIR and
LRpSVSpSYGNIR, respectively. Fragment ions indicated correspond to y-type cleavages.
(E) Schematic representation of the identified phosphorylation sites within Raptor.
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1272overexpression of wild-type ERK2 increased Raptor phos-
phorylation upon PMA stimulation (Figure 2D), demonstrating
that oncogenic and mitogenic stimulations of the Ras/MAPK
pathway promote Raptor phosphorylation. Importantly, we
show that activated MEK-induced Raptor phosphorylation
was drastically inhibited by both the BI-D1870 inhibitor and
RSK 1 and 2 RNAi (Figure 2E), demonstrating the requirement
for RSK in Raptor phosphorylation induced by oncogenic Ras/
MAPK signaling.
Ser719, Ser721, and Ser722 Are the Predominant
RSK-Dependent Phosphorylation Sites in Raptor
To identify RXRXXpS/T phosphorylation sites in Raptor, we
performed quantitative mass spectrometry (MS) analyses onimmunoprecipitated Myc-tagged Raptor derived from unsti-
mulated and PMA-stimulated cells. We performed combined
ion profiling and MS/MS peptide sequencing analyses to corre-
late abundance changes of identified phosphopeptides across
the different experimental paradigms (Figure 3A). Using this
approach, we identified two phosphopeptides corresponding
to phosphorylated Ser719 and Ser722, showing more than a
10-fold change in phosphorylation upon PMA stimulation
(Figure 3B). In contrast to these findings, another phosphopep-
tide (Ser877) identified in this study showed no statistically
significant change in phosphorylation upon PMA stimulation.
Importantly, treatment of cells with either U0126 or BI-D1870
significantly decreased the relative abundance of the singly
and doubly phosphorylated peptides (Figure 3B), thereby
Figure 4. Ser719, Ser721, and Ser722 are the
Primary RSK-Dependent Phosphorylation Sites
in Raptor
(A) Schematic representation of the consensus
motifs encompassing residues Ser719, Ser721,
and Ser722 of Raptor.
(B) Primary sequence alignment showing conser-
vation of the three RSK-dependent phosphoryla-
tion sites within different Raptor orthologs.
(C) HEK293 cells were transfected with wild-type
Raptor or potential RSK-phosphorylation-site
mutants S719A, S721A, S722A, and the triple
mutant S719/721/722A (3A), serum starved, and
stimulated with PMA for 20 min. Immunoprecipi-
tated Raptor was then immunoblotted for phos-
phorylation at RXRXXpS/T sites.
(D) As in (C), except cells were transfected with
wild-type, 3A, or potential RSK-phosphoryla-
tion-site mutants (S59A and S791A) that were
not identified by MS analysis. Raptor immuno-
precipitates were then immunoblotted for phos-
phorylation at RXRXXpS/T sites.
(E) As in Figure 2D, except that HA-tagged wild-
type RSK1 immunoprecipitates were incubated
with either wild-type Raptor or the 3A mutant in
an in vitro kinase reaction.
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1273confirming that phosphorylation of Ser719 and Ser722 requires
MEK- and RSK-dependent signaling. Identification of Ser719
and Ser722 as phosphorylation sites was obtained by MS/MS
sequencing, and the assignment is shown for these residues
in the corresponding tryptic peptides (Figures 3C and 3D).
Importantly, similar findings were obtained when endogenous
Raptor was immunoprecipitated from cells and analyzed via
this method (data not shown). Ser719 and Ser722 are located
close to the HEAT repeats of Raptor (Figure 3E), suggesting
that this region integrates upstream signals that may regulate
Raptor function.
To determine whether RSK targets Ser719 and Ser722 for
phosphorylation, we mutated these sites to unphosphorylat-
able alanine residues (S719A and S722A). Although it was
not reproducibly identified by MS, we also mutated nearby
Ser721 because this residue lies within an optimal RSK con-
sensus sequence (Figure 4A). Interestingly, all three serine res-
idues are conserved in organisms from Drosophila to humans
(Figure 4B), suggesting that they play an important and evolu-
tionarily conserved function. Although mutation of Ser721 only
slightly but reproducibly reduced Raptor phosphorylation, we
found that mutation of either Ser719 or Ser722 drastically de-
creased the phosphorylation of Raptor after PMA stimulation
(Figure 4C). Importantly, when combined into a single Raptor
mutant (S719/721/722A, from here on termed 3A), mutation
of all three serine residues completely inhibited Raptor phos-
phorylation upon stimulation of the Ras/MAPK pathway. We
also analyzed the potential involvement of additional putative
RXRXXpS/T phosphorylation sites in Raptor. Importantly,
mutagenesis of Ser59 and Ser791 did not reduce Raptor phos-
phorylation after PMA stimulation (Figure 4D), indicating that
RSK does not phosphorylate these residues in cells. The spec-
ificity of RSK toward Ser719, Ser721, and Ser722 was also con-
firmed in vitro. Mutation of all three residues almost completelyinhibited RSK-mediated [32P] incorporation in immunopurified
full-length Raptor (Figure 4E) and in recombinant GST-Raptor
(Figure S1C), confirming that RSK predominantly phosphory-
lates Raptor at these residues both in vitro and in vivo.
Raptor Phosphorylation Regulates mTORC1 Activity
To assess whether Raptor phosphorylation regulates its asso-
ciation with mTOR or the recruitment of mTOR substrates, we
transfected cells with wild-type or 3A Raptor and assessed as-
sociation of mTOR, S6K1, and 4E-BP1 after immunoprecipita-
tion. Interestingly, we found that the Raptor 3A mutant bound
as efficiently as wild-type Raptor to 4E-BP1 (Figure 5A) and
S6K1 (Figure S3), indicating that Raptor phosphorylation
does not regulate TOS-motif-mediated binding. To determine
whether Raptor phosphorylation affected its interaction with
mTOR, we transfected cells with mTOR and wild-type or 3A
Raptor and assessed the presence of mTOR within Raptor im-
munoprecipitates by immunoblotting. As shown in Figure 5B,
we found that the Raptor 3A mutant bound as efficiently as
wild-type Raptor to mTOR, indicating that phosphorylation of
these residues does not regulate Raptor-mTOR interactions.
Next, we determined whether Raptor phosphorylation regu-
lates mTORC1 activity by using an in vitro mTOR phospho-
transferase activity assay and recombinant GST-4E-BP1 as
a substrate. Our assay specifically monitored mTORC1 activity
given that 4E-BP1 phosphorylation was exclusively detected
within Raptor immunoprecipitates (Figure 5C), was sensitive
to rapamycin treatment (Figure S4A), and required a functional
mTOR kinase domain (Figure S4B). Under these conditions,
activation of the Ras/MAPK pathway with PMA robustly stim-
ulated mTORC1 activity (Figure 5D). Importantly, we found that
mTOR kinase activity associated with the Raptor 3A mutant
was dramatically lower than that associated with wild-type
Raptor, suggesting that Raptor phosphorylation by RSK
Figure 5. RSK-Mediated Phosphorylation of Raptor Promotes mTORC1 Activity without Altering Raptor Interaction with mTOR or Its Substrates
(A) Cells were cotransfected with HA-tagged 4E-BP1 and either wild-type Raptor or the 3A mutant, serum starved, and stimulated with PMA. Associated
4E-BP1 was assayed within Raptor immunoprecipitates by immunoblotting.
(B) Cells were cotransfected with Flag-tagged mTOR and either wild-type Raptor or the 3A mutant, serum starved, and stimulated with PMA. Associated
mTOR was assayed within Raptor immunoprecipitates.
(C) Cells were cotransfected with mTOR and Raptor and serum starved, and mTORC1 kinase activity was assayed within Raptor immunoprecipitates, with
GST-4EBP1 as a substrate. The kinase reaction was performed in the presence of g[32P]ATP, the resulting samples were subjected to SDS-PAGE, and the
dried Coomassie-stained gel was autoradiographed.
(D) Cells were cotransfected with mTOR and wild-type Raptor or the 3A mutant, serum starved, and stimulated with PMA. mTORC1 activity was assayed as
described in (A).
(E) As in (D), except that cells were stimulated with insulin (100 nM) for 20 min.
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1274positively stimulates mTORC1 activity. Because we found that
insulin did not stimulate Raptor phosphorylation, we were in-
terested in determining whether insulin-stimulated mTORC1
activity was affected by mutation of Raptor. Interestingly, we
found that insulin stimulation led to comparable activation of
mTORC1 in cells expressing wild-type or 3A Raptor (Figure 5E).
The role of RSK in Ras/MAPK-dependent activation of
mTORC1 was confirmed by the finding that overexpression
of all RSK isoforms increases the phosphorylation of S6K
and 4E-BP1 on Thr389 and on Thr37 and Thr46, respectively,
sites known to be exclusively phosphorylated by activated
mTOR (Figure S2A). Consistent with a positive role for RSK
in mTORC1 activation, we found that BI-D1870 treatment
decreased PMA-induced activation of mTORC1, as reflected
by a reduction in phosphorylation of S6K and 4E-BP1 (Figure-
S2B), as well as S6 on Ser240/244 (Figures 1C snf 2E; Fig-
ure S2B), residues that are exclusively phosphorylated by
activated S6K, as previously reported [25].
These data support a novel and specific role for the
Ras/MAPK pathway in mTORC1 activation; in this role,
RSK-mediated phosphorylation of Raptor promotes mTORC1
activity independently of the PI3K/Akt pathway (Figure 6).
Discussion
Our findings demonstrate that the Ras/MAPK pathway regu-
lates mTOR signaling via a twofold mechanism. Although pre-
vious studies indicated that both ERK and RSK stimulate Rheb
GTP-loading through the inactivation of TSC2 [17–19], we show
herein that RSK also directly targets the mTORC1 complex by
phosphorylating Raptor and thereby promoting mTORC1 ki-
nase activity (Figure 6). RSK phosphorylates three evolution-
arily conserved Raptor serine residues that lie within a region
with no homology to known functional domains. Our findings
suggest that this region might play a novel function in confer-
ring the capacity to respond to upstream signaling. Whereas
Ser721 lies within a classical RSK consensus sequence
(RXRXXpS/T), Ser719 is located within a minimal phosphoac-
ceptor sequence (RXXpS) that was found to be sufficient in
other RSK substrates, such as DAPK, c-Fos, and CREB [20,
21]. Interestingly, Ser722 is located at the +1 position of the
classical RSK consensus motif, suggesting that under some
circumstances, RSK efficiently phosphorylates residues lo-
cated just outside of its consensus. We have previously found
that RSK promotes phosphorylation of TSC2 at both Ser1798
and Ser1799, and this represents another situation in which
RSK specificity can extend to the +1 serine residue (P.P.R.
and B. Ballif, unpublished observation) [18].
Whereas mutation of Raptor at RSK-dependent phosphory-
lation sites did not reduce its ability to interact with mTOR or
TOS-motif-containing substrates (4E-BP1 and S6K1), our
data indicate that these phosphorylation events strongly and
positively regulate mTORC1 kinase activity. These findings
suggest that Raptor phosphorylation modulates mTORC1
Figure 6. The Ras/MAPK and PI3K/Akt Pathways Regulate mTORC1
Activation by a Twofold Mechanism
Although Akt and RSK inactivate TSC2 and thereby promote Rheb
GTP-loading, both kinases also directly regulate mTORC1 via alternative
mechanisms. Whereas Akt phosphorylates PRAS40 to suppress its inhibi-
tory function, RSK directly phosphorylates Raptor to promote mTORC1
activity.
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mTOR and at least some of its substrates. Recent structural
evidence indicates that the C-terminal region of Raptor’s yeast
analog (named KOG-1), including the HEAT and WD40 re-
peats, closely interact with the N-terminal portion of TOR
[27]. The position of the RSK phosphorylation sites on Raptor
suggests that they could lead the mTOR-Raptor complex to
undergo a conformational change that would allow activation
of the catalytic activity of mTOR. This could result from spe-
cific association or dissociation of regulatory proteins to or
from the mTORC1 complex, leading to the direct regulation
of mTOR activity. Another possibility is that Raptor phosphor-
ylation could suppress the activity or interaction of mTORC1
with a negative regulator and therefore promote mTORC1
activity. Although many studies have investigated the up-
stream regulation of mTORC1, very few have reported the reg-
ulation of mTOR activity through the direct modification of
mTORC1 constituents. The PI3K/Akt pathway was shown to
directly regulate mTORC1 activity via the phosphorylation of
PRAS40, a component of the mTORC1 complex [28, 29].
Although PRAS40 phosphorylation at Thr246 was not found
to be regulated by Ras/MAPK signaling [30], we have also de-
termined that PRAS40 binding to Raptor was unaltered by
RSK-mediated phosphorylation (data not shown). It has re-
cently been demonstrated that Raptor phosphorylation by
AMPK negatively controls mTORC1 activity [31]. Together
with the present study, these new findings suggest that, as
for TSC2, Raptor appears to be a major signal integrator that
interprets cell growth cues as well as energy sufficiency.
Our findings also highlight the interrelation between the Ras/
MAPK and mTOR pathways, both frequently deregulated in
human cancers. Hyperactivation of mTOR has been described
in several cancers harboring oncogenic activation of Ras [4, 5,
32], and mTORC1 activity has been shown to be essential for
Ras-mediated proliferation and transformation [33]. Although
the molecular mechanisms at the origin of mTOR hyperactiva-
tion in cancer cells remain to be fully elucidated, the constitu-
tive Raptor phosphorylation observed in cells expressing
oncogenic forms of Ras and MEK suggests that rapamycin
may be of therapeutic value for the treatment of cancers with
activating mutations in the Ras/MAPK pathway.
Experimental Procedures
Cell Culture and Transfection
HEK293, HeLa, and NIH 3T3 cells were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS) and antibiotics. HEK293 and NIH 3T3
cells were transfected with calcium-phosphate as described previously
[18]. HeLa cells were transfected with Fugene (Roche) according to the
manufacturer’s instructions. Cells were grown for 24 hr after transfection
and starved of serum where indicated for 16–18 hr. Starved cells were
pretreated with wortmannin (100 nM), U0126 (10 mM), rapamycin (100 nM)
(Biomol, Plymouth Meeting, PA), or BI-D1870 (10 mM) [23] and stimulated
with either FBS (10%), insulin (100 nM), epidermal growth factor (EGF;
50 ng/ml) (Invitrogen), or phorbol 13-myristate 12-acetate (PMA; 25-
100 ng/ml)(Biomol) before being harvested.
Immunoprecipitations and Immunoblotting
Cell lysates were prepared as described previously [18]. For mTOR immuno-
precipitations, cells were harvested in CHAPS lysis buffer (40 mM HEPES
[pH 7.4], 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM b-glycerophos-
phate, and 0.3% CHAPS). Immunoprecipitations were carried out with the
indicated antibody for 2 hr followed by 1 hr incubation with Protein A-Se-
pharose CL-4B beads (GE Healthcare). Immunoprecipitates were washed
thrice in lysis buffer and, along with total cell lysates, were subjected to
SDS-PAGE and electroblotted onto nitrocellulose. The data presented are
representative of at least three independent experiments.
In Vitro Kinase Reactions
RSK in vitro kinase assays were performed as previously described [18] with
immunopurified Myc-Raptor (2 mg per assay) or bacterially purified recombi-
nant GST-Raptor (2 mg per assay). For mTOR kinase assays, beads from
immunoprecipitations were washed thrice in CHAPS lysis buffer and then
thrice in CHAPS buffer supplemented with 150 mM NaCl. Assays were per-
formed for 30 min at 30C with bacterially purified recombinant GST-4EBP1
(2 mg per assay) and 10 mCi g[32P]-ATP in mTOR kinase buffer (25 mM HEPES
[ph 7.4], 50 mM NaCl, 50 mM b-glycerophosphate, 10 mM MnCl2, 100 mM
cold ATP). All samples were subjected to SDS-PAGE, and incorporation of
cold or radioactive phosphate [32P] was determined by immunoblotting or
quantified by use of a Fuji PhosphorImager with ImageQuant software.
The data presented are representative of at least three independent
experiments.
RNA Interference
For the small interfering RNA (siRNA) studies, 21 nucleotide complementary
RNA with symmetrical 2 nt overhangs were obtained from QIAGEN (Valen-
cia, CA). The DNA sequences against which RNA duplexes were created
for RSK1 and RSK2 and the scrambled control were described elsewhere
[25, 34, 35]. For transfection of HEK293 cells, calcium-phosphate and
50 nM siRNA per dish were used. Transfection efficiency was determined
to be greater than 90% by a fluorescently-labeled mock siRNA.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and
four figures and are available with this article online at http://www.
current-biology.com/cgi/content/full/18/17/1269/DC1/.
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